Masoumeh Asgharpour
1 
, Mohammad Ebrahimi Kalan
2 , Seyed Hadi Mirhashemi
3, Amirhesam Alirezaei
4* 1 Department of Nephrology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
2 Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, FL, USA
3 Department of Surgery, Loghman hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Urology and Nephrology Research Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive
medications. They are indicated in the management of multiple chronic conditions including hypertension,
diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin
catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis.
The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.